Sotatercept
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Pulmonary Arterial Hypertension
Conditions
Pulmonary Arterial Hypertension
Trial Timeline
Dec 1, 2021 → Feb 18, 2025
NCT ID
NCT04896008About Sotatercept
Sotatercept is a phase 3 stage product being developed by Merck for Pulmonary Arterial Hypertension. The current trial status is completed. This product is registered under clinical trial identifier NCT04896008. Target conditions include Pulmonary Arterial Hypertension.
What happened to similar drugs?
20 of 20 similar drugs in Pulmonary Arterial Hypertension were approved
Approved (20) Terminated (1) Active (0)
✅Arformoterol Tartrate Inhalation Solution + Arformoterol Tartrate Inhalation Solution + PlaceboSumitomo PharmaApproved
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (12)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07140484 | Approved | Recruiting |
| NCT06658522 | Approved | Recruiting |
| NCT06814145 | Phase 2 | Recruiting |
| NCT06843460 | Phase 1 | Completed |
| NCT05818137 | Phase 3 | Completed |
| NCT05587712 | Phase 2 | Recruiting |
| NCT04811092 | Phase 3 | Completed |
| NCT04896008 | Phase 3 | Completed |
| NCT07218029 | Phase 3 | Recruiting |
| NCT03738150 | Phase 2 | Completed |
| NCT01736683 | Phase 2 | Completed |
| NCT01190644 | Phase 2 | Terminated |
Competing Products
20 competing products in Pulmonary Arterial Hypertension